(BLLN) BillionToOne, Common Stock - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 3.963m USD | Total Return: -15.6% in 12m
Avg Turnover: 56.0M
Rev. Trend: 100.0%
Warnings
P/E ratio 159.5
Volatile Below Avwap Earnings
Tailwinds
Confidence
BillionToOne, Inc. (BLLN) is a Menlo Park-based precision diagnostics firm specializing in molecular counting technology. The company’s proprietary platform enables the detection of DNA molecules at a single-count resolution, facilitating high-sensitivity testing across prenatal and oncology clinical pathways.
The product portfolio includes UNITY Complete for non-invasive prenatal screening and the Northstar suite for liquid biopsy and treatment monitoring. Unlike traditional tissue biopsies, liquid biopsies utilize circulating tumor DNA (ctDNA) to identify genetic mutations and monitor therapeutic efficacy through simple blood draws. This sector is characterized by high research and development requirements and a transition toward value-based reimbursement models in genomic medicine.
Investors can further evaluate these market dynamics and financial metrics by exploring ValueRay.
- UNITY prenatal screening adoption rates drive core diagnostic revenue growth
- Commercial insurance coverage expansion determines molecular counting platform profitability
- Clinical trial data for Northstar Response influences oncology market penetration
- Regulatory shifts in LDT oversight impact diagnostic validation and compliance costs
- R&D spending on single-molecule counting technology affects long-term operating margins
| Net Income: 25.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 21.49 > 1.0 |
| NWC/Revenue: 159.9% < 20% (prev 109.9%; Δ 50.03% < -1%) |
| CFO/TA 0.05 > 3% & CFO 38.1m > Net Income 25.2m |
| Net Debt (-339.1m) to EBITDA (48.1m): -7.06 < 3 |
| Current Ratio: 10.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.0m) vs 12m ago 18.58% < -2% |
| Gross Margin: 70.40% > 18% (prev 0.57%; Δ 6.98k% > 0.5%) |
| Asset Turnover: 69.97% > 50% (prev 57.13%; Δ 12.84% > 0%) |
| Interest Coverage Ratio: 556.5 > 6 (EBITDA TTM 48.1m / Interest Expense TTM 65.0k) |
| A: 0.81 (Total Current Assets 624.1m - Total Current Liabilities 57.2m) / Total Assets 700.7m |
| B: -0.37 (Retained Earnings -256.8m / Total Assets 700.7m) |
| C: 0.07 (EBIT TTM 36.2m / Avg Total Assets 506.7m) |
| D: -1.33 (Book Value of Equity -258.6m / Total Liabilities 195.1m) |
| Altman-Z'' = 3.20 = A |
| DSRI: 1.01 (Receivables 61.3m/30.4m, Revenue 354.5m/178.6m) |
| GMI: 0.81 (GM 70.40% / 57.35%) |
| AQI: 0.27 (AQ_t 0.01 / AQ_t-1 0.03) |
| SGI: 1.98 (Revenue 354.5m / 178.6m) |
| TATA: -0.02 (NI 25.2m - CFO 38.1m) / TA 700.7m) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 84.48 with a total of 698,991 shares traded.
Over the past week, the price has changed by -1.90%,
over one month by +3.33%,
over three months by +18.30% and
over the past year by -15.55%.
BillionToOne, Common Stock has no consensus analysts rating.
P/E Trailing = 159.537
P/S = 11.1467
P/B = 7.816
Revenue TTM = 354.5m USD
EBIT TTM = 36.2m USD
EBITDA TTM = 48.1m USD
Long Term Debt = 90.0m USD (from longTermDebt, last quarter)
Short Term Debt = 6.24m USD (from shortTermDebt, last quarter)
Debt = 198.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 54.2m
Net Debt = -339.1m USD (calculated: Debt 198.4m - CCE 537.5m)
Enterprise Value = 3.62b USD (3.96b + Debt 198.4m - CCE 537.5m)
Interest Coverage Ratio = 556.5 (Ebit TTM 36.2m / Interest Expense TTM 65.0k)
EV/FCF = 79.21x (Enterprise Value 3.62b / FCF TTM 45.7m)
FCF Yield = 1.26% (FCF TTM 45.7m / Enterprise Value 3.62b)
FCF Margin = 12.90% (FCF TTM 45.7m / Revenue TTM 354.5m)
Net Margin = 7.11% (Net Income TTM 25.2m / Revenue TTM 354.5m)
Gross Margin = 70.40% ((Revenue TTM 354.5m - Cost of Revenue TTM 105.0m) / Revenue TTM)
Gross Margin QoQ = 72.97% (prev 71.42%)
Tobins Q-Ratio = 5.17 (Enterprise Value 3.62b / Total Assets 700.7m)
Interest Expense / Debt = 0.03% (Interest Expense 65.0k / Debt 198.4m)
Taxrate = 2.91% (539k / 18.5m)
NOPAT = 35.1m (EBIT 36.2m * (1 - 2.91%))
Current Ratio = 9.48 (Total Current Assets 624.1m / Total Current Liabilities 65.9m)
Debt / Equity = 0.39 (Debt 198.4m / totalStockholderEquity, last quarter 505.6m)
Debt / EBITDA = -7.06 (Net Debt -339.1m / EBITDA 48.1m)
Debt / FCF = -7.41 (Net Debt -339.1m / FCF TTM 45.7m)
Total Stockholder Equity = 333.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.98% (Net Income 25.2m / Total Assets 700.7m)
RoE = 4.27% (Net Income TTM 25.2m / Total Stockholder Equity 590.5m)
RoCE = 5.32% (EBIT 36.2m / Capital Employed (Equity 590.5m + L.T.Debt 90.0m))
RoIC = 5.92% (NOPAT 35.1m / Invested Capital 592.9m)
WACC = 10.98% (E(3.96b)/V(4.16b) * Re(11.53%) + D(198.4m)/V(4.16b) * Rd(0.03%) * (1-Tc(0.03)))
Discount Rate = 11.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.29 | Cagr: 824.1%
[DCF] Terminal Value 66.80% ; FCFF base≈45.7m ; Y1≈45.9m ; Y5≈48.7m
[DCF] Fair Price = 20.80 (EV 522.9m - Net Debt -339.1m = Equity 861.9m / Shares 41.4m; r=10.98% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.97 | Revenue CAGR: 106.2% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.16 | Chg30d=+45.45% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.24 | Chg30d=+28.95% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.87 | Chg30d=+72.28% | Revisions=+20% | GrowthEPS=+66.5% | GrowthRev=+48.9%
EPS next Year (2027-12-31): EPS=1.03 | Chg30d=+15.08% | Revisions=-20% | GrowthEPS=+18.4% | GrowthRev=+27.7%
[Analyst] Revisions Ratio: +20%